UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Advancements in targeted therapies for generalized acetylcholine receptor antibody positive myasthenia gravis: Beginnings of a paradigm shift

European journal of neurology, 2023-12, Vol.30 (12), p.3644-3645

2023

Volltextzugriff (PDF)

Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy

European journal of neurology, 2024-06, Vol.31 (6), p.e16180-n/a

2024

Volltextzugriff (PDF)

Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A prospective cohort study of different CIDP subtypes and disease stages

European journal of neurology, 2022-02, Vol.29 (2), p.583-592

2022

Volltextzugriff (PDF)

Report of a fulminant anti‐pan‐neurofascin‐associated neuropathy responsive to rituximab and bortezomib

Journal of the peripheral nervous system, 2021-12, Vol.26 (4), p.475-480

2021

Volltextzugriff (PDF)

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

Journal of Neurology, 2016-08, Vol.263 (8), p.1473-1494

2016

Volltextzugriff (PDF)

Understanding the burden of refractory myasthenia gravis

Therapeutic Advances in Neurological Disorders, 2019, Vol.12, p.1756286419832242

2019

Volltextzugriff (PDF)

Advances and challenges in the treatment of myasthenia gravis

Therapeutic Advances in Neurological Disorders, 2021, Vol.14, p.17562864211065406-17562864211065406

2021

Volltextzugriff (PDF)

Cortical and Subcortical Grey and White Matter Atrophy in Myotonic Dystrophies Type 1 and 2 Is Associated with Cognitive Impairment, Depression and Daytime Sleepiness

PloS one, 2015-06, Vol.10 (6), p.e0130352-e0130352

2015

Volltextzugriff (PDF)

The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease

Brain (London, England : 1878), 2011-12, Vol.134 (12), p.3527-3543

2011

Volltextzugriff (PDF)

Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients

Annals of clinical and translational neurology, 2021-05, Vol.8 (5), p.1110-1121

2021

Volltextzugriff (PDF)

Tracking the brain in myotonic dystrophies: A 5-year longitudinal follow-up study

PloS one, 2019-03, Vol.14 (3), p.e0213381-e0213381

2019

Volltextzugriff (PDF)

Glia cells in amyotrophic lateral sclerosis: New clues to understanding an old disease?

Muscle & nerve, 2007-06, Vol.35 (6), p.712-724

2007

Volltextzugriff (PDF)

Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab

JAMA neurology, 2013-08, Vol.70 (8), p.1056

2013

Volltextzugriff (PDF)

Correlates of polyneuropathy in Parkinson’s disease

Annals of clinical and translational neurology, 2020-10, Vol.7 (10), p.1898-1907

2020

Volltextzugriff (PDF)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience

Therapeutic advances in neurological disorders, 2017-10, Vol.10 (10), p.339-341

2017

Volltextzugriff (PDF)

Skin Ceramide Alterations in First-Episode Schizophrenia Indicate Abnormal Sphingolipid Metabolism

Schizophrenia bulletin, 2013-07, Vol.39 (4), p.933-941

2013

Volltextzugriff (PDF)

Characterization of Iron Accumulation in Deep Gray Matter in Myotonic Dystrophy Type 1 and 2 Using Quantitative Susceptibility Mapping and R2 Relaxometry: A Magnetic Resonance Imaging Study at 3 Tesla

Frontiers in neurology, 2019-12, Vol.10, p.1320-1320

2019

Volltextzugriff (PDF)

Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG)

Therapeutic Advances in Neurological Disorders, 2020, Vol.13, p.1756286420949808-1756286420949808

2020

Volltextzugriff (PDF)

Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

BMC neurology, 2021-12, Vol.21 (1), p.1-467, Article 467

2021

Volltextzugriff (PDF)

The association of vagal atrophy with parameters of autonomic function in multiple system atrophy and progressive supranuclear palsy

Therapeutic advances in neurological disorders, 2024-01, Vol.17, p.17562864241267300

2024

Volltextzugriff (PDF)

Joint analysis as an important tool for an optimizing block extraction of natural stones

Environmental earth sciences, 2022-02, Vol.81 (3), Article 94

2022

Volltextzugriff (PDF)

Guideline for the management of myasthenic syndromes

Therapeutic Advances in Neurological Disorders, 2023-01, Vol.16, p.17562864231213240-17562864231213240

2023

Volltextzugriff (PDF)

Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1

Experimental cell research, 2008-07, Vol.314 (11), p.2266-2278

2008

Volltextzugriff (PDF)

Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy

European journal of neurology, 2024-04, Vol.31 (4), p.e16205-n/a

2024

Volltextzugriff (PDF)

Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study

Therapeutic advances in neurological disorders, 2021, Vol.14, p.1756286421999631-1756286421999631

2021

Volltextzugriff (PDF)

1 – 25 von 1.467

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(636)
Mit Volltextzugriff
(1.337)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(44)

Menü

Weitere Dienste

Einstellungen

Advancements in targeted therapies for generalized acetylcholine receptor antibody positive myasthenia gravis: Beginnings of a paradigm shift

Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy

Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A prospective cohort study of different CIDP subtypes and disease stages

Report of a fulminant anti‐pan‐neurofascin‐associated neuropathy responsive to rituximab and bortezomib

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

Understanding the burden of refractory myasthenia gravis

Advances and challenges in the treatment of myasthenia gravis

Cortical and Subcortical Grey and White Matter Atrophy in Myotonic Dystrophies Type 1 and 2 Is Associated with Cognitive Impairment, Depression and Daytime Sleepiness

The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease

Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients

Tracking the brain in myotonic dystrophies: A 5-year longitudinal follow-up study

Glia cells in amyotrophic lateral sclerosis: New clues to understanding an old disease?

Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab

Correlates of polyneuropathy in Parkinson’s disease

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience

Skin Ceramide Alterations in First-Episode Schizophrenia Indicate Abnormal Sphingolipid Metabolism

Characterization of Iron Accumulation in Deep Gray Matter in Myotonic Dystrophy Type 1 and 2 Using Quantitative Susceptibility Mapping and R2 Relaxometry: A Magnetic Resonance Imaging Study at 3 Tesla

Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG)

Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

The association of vagal atrophy with parameters of autonomic function in multiple system atrophy and progressive supranuclear palsy

Joint analysis as an important tool for an optimizing block extraction of natural stones

Guideline for the management of myasthenic syndromes

Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1

Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy

Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study

Suchergebnisse filtern